Q-omics provides the consensus-scored C4orf51 profile across patient tissues and cancer cell-line models. C4orf51 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, C4orf51 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, C4orf51 RNA expression shows 7,658 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, THCA, and TGCT as cancer lineages where C4orf51 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C4orf51 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C4orf51 survival associations across molecular data types. C4orf51 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C4orf51 RNA expression–survival associations across cancer types. High C4orf51 expression shows unfavorable associations in ACC, SCLC, LGG and BRCA, but favorable associations in LUAD and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for C4orf51 RNA expression.
This table summarizes C4orf51 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for C4orf51. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C4orf51 shows lower tumor expression in THCA and higher tumor expression in HNSC, KICH, LUSC, BRCA and KIRC. The THCA box plot shows higher C4orf51 RNA expression in normal versus tumor tissue (log2 FC = −0.347, t-test p < 0.001).
This table shows molecular features associated with C4orf51 in patient tissues and cancer cell lines. In patient samples, C4orf51 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, C4orf51 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
